Sophie Brachat

Sophie Brachat

Auto-generated profile, based on publicly available information

Sophie Brachat

Musculoskeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2002 in Nature
Verified
Journal Article
Open access
PDF file
GGGuri Giaever
Guri Giaever
ACAngela M. Chu
Angela M. Chu
LNLi Ni
Li Ni
CCCarla Connelly
Carla Connelly
LRLinda Riles
Linda Riles
MJMark Johnston
Mark Johnston
Determining the effect of gene deletion is a fundamental approach to understanding gene function. Conventional genetic screens exhibit biases, and genes contributing to a phenotype are often missed. We systematically constructed a nearly complete collection of gene-deletion mutants (96% of annotated open reading frames, or ORFs) of the yeast Saccharomyces cerevisiae. DNA sequences dubbed ‘molecular bar codes’ uniquely identify each strain, enabling their growth to be analysed in parallel and the fitness contribution of each gene to be quantitatively assessed by hybridization to high-density oligonucleotide arrays. We show that previously known and new genes are necessary for optimal growth under six well-studied conditions: high salt, sorbitol, galactose, pH 8, minimal medium and nystatin treatment. Less than 7% of genes that exhibit a significant increase in messenger RNA expression are also required for optimal growth in four of the tested conditions. Our results validate the yeast gene-deletion collection as a valuable resource for functional genomics.

9 April 2004 in Science
Verified
Journal Article
Closed access
PDF file
FDFred S. Dietrich
Fred S. Dietrich
SVSylvia Voegeli
Sylvia Voegeli
SBSophie Brachat
Sophie Brachat
ALAnita Lerch
Anita Lerch
KGKrista Gates
Krista Gates
PPPeter Philippsen
Peter Philippsen
We have sequenced and annotated the genome of the filamentous ascomycete Ashbya gossypii . With a size of only 9.2 megabases, encoding 4718 protein-coding genes, it is the smallest genome of a free-living eukaryote yet characterized. More than 90% of A. gossypii genes show both homology and a particular pattern of synteny with Saccharomyces cerevisiae . Analysis of this pattern revealed 300 inversions and translocations that have occurred since divergence of these two species. It also provided compelling evidence that the evolution of S. cerevisiae included a whole genome duplication orfusion of two related species and showed, through inferred ancient gene orders, which of the duplicated genes lost one copy and which retained both copies.

1 July 2015 in Cell Metabolism
Verified
Journal Article
Closed access
MEMarc A. Egerman
Marc A. Egerman
SCSamuel M. Cadena
Samuel M. Cadena
JGJason A. Gilbert
Jason A. Gilbert
AMAngelika Meyer
Angelika Meyer
HNHallie N. Nelson
Hallie N. Nelson
DGDavid J. Glass
David J. Glass

1 February 2014 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
ELEstelle Lach-Trifilieff
Estelle Lach-Trifilieff
GMGiulia C. Minetti
Giulia C. Minetti
KSKellyAnn Sheppard
KellyAnn Sheppard
CIChikwendu Ibebunjo
Chikwendu Ibebunjo
JFJerome N. Feige
Jerome N. Feige
DGDavid J. Glass
David J. Glass
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.

1 January 2013 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
CIChikwendu Ibebunjo
Chikwendu Ibebunjo
JCJoel M. Chick
Joel M. Chick
TKTracee Kendall
Tracee Kendall
JEJohn K. Eash
John K. Eash
CLChristine Li
Christine Li
DGDavid J. Glass
David J. Glass
Molecular mechanisms underlying sarcopenia, the age-related loss of skeletal muscle mass and function, remain unclear. To identify molecular changes that correlated best with sarcopenia and might contribute to its pathogenesis, we determined global gene expression profiles in muscles of rats aged 6, 12, 18, 21, 24, and 27 months. These rats exhibit sarcopenia beginning at 21 months. Correlation of the gene expression versus muscle mass or age changes, and functional annotation analysis identified gene signatures of sarcopenia distinct from gene signatures of aging. Specifically, mitochondrial energy metabolism (e.g., tricarboxylic acid cycle and oxidative phosphorylation) pathway genes were the most downregulated and most significantly correlated with sarcopenia. Also, perturbed were genes/pathways associated with neuromuscular junction patency (providing molecular evidence of sarcopenia-related functional denervation and neuromuscular junction remodeling), protein degradation, and inflammation. Proteomic analysis of samples at 6, 18, and 27 months confirmed the depletion of mitochondrial energy metabolism proteins and neuromuscular junction proteins. Together, these findings suggest that therapeutic approaches that simultaneously stimulate mitochondrogenesis and reduce muscle proteolysis and inflammation have potential for treating sarcopenia.

1 June 2005 in Eukaryotic Cell
Verified
Journal Article
Open access
PDF file
CHCharles Hall
Charles Hall
SBSophie Brachat
Sophie Brachat
FDFred S. Dietrich
Fred S. Dietrich
The genomes of the hemiascomycetes Saccharomyces cerevisiae and Ashbya gossypii have been completely sequenced, allowing a comparative analysis of these two genomes, which reveals that a small number of genes appear to have entered these genomes as a result of horizontal gene transfer from bacterial sources. One potential case of horizontal gene transfer in A. gossypii and 10 potential cases in S. cerevisiae were identified, of which two were investigated further. One gene, encoding the enzyme dihydroorotate dehydrogenase (DHOD), is potentially a case of horizontal gene transfer, as shown by sequencing of this gene from additional bacterial and fungal species to generate sufficient data to construct a well-supported phylogeny. The DHOD-encoding gene found in S. cerevisiae , URA1 (YKL216W), appears to have entered the Saccharomycetaceae after the divergence of the S. cerevisiae lineage from the Candida albicans lineage and possibly since the divergence from the A. gossypii lineage. This gene appears to have come from the Lactobacillales , and following its acquisition the endogenous eukaryotic DHOD gene was lost. It was also shown that the bacterially derived horizontally transferred DHOD is required for anaerobic synthesis of uracil in S. cerevisiae. The other gene discussed in detail is BDS1 , an aryl- and alkyl-sulfatase gene of bacterial origin that we have shown allows utilization of sulfate from several organic sources. Among the eukaryotes, this gene is found in S. cerevisiae and Saccharomyces bayanus and appears to derive from the alpha-proteobacteria.